INCY vs ZVRA · P/E 14, rev $5.14B vs P/E 6.3, rev $75.9M
Incyte Corporation (INCY) versus Zevra Therapeutics Inc. (ZVRA) — a side-by-side from cached financials, not a winner call.
Incyte Corporation (INCY) is a biotechnology company listed on US.
Zevra Therapeutics Inc. (ZVRA) is a biotechnology company listed on NASDAQ.
Latest reported INCY revenue for 2025-12-31 was $5.14B. Net income was $1.29B. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
Latest reported ZVRA revenue for 2026-06-30 was $75.9M. Net income was $46.6M. ZVRA currently screens at market cap $745.4M and trailing P/E 6.3.
INCY currently screens at market cap $20.45B and trailing P/E 14.5. ZVRA currently screens at market cap $745.4M and trailing P/E 6.3.
Not investment advice. Open the INCY and ZVRA stock pages for the full models.
Not investment advice.